个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Fang, W.[1] * ; Zhao, S.[1,10] ; Liang, Y.[1] ; Yang, Y.[1,7] ; Yang, L.[2] ; Dong, X.[3] ; Zhang, L.[1,4] ; Tang, Y.[5] ; Wang, S.[6] ; Yang, Y.[1,7] ; Ma, X.[8] ; Wang, M.[9] ; Wang, W.[10] ; Zhao, S.[1,10] ; Wang, K.[10] ; Gao, S.[8] ; Zhang, L.[1,4] ;
单位： [1]Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China [2]Jinan Univ, Dept Thorac Surg, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Peoples R China [3]Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Coll Med, Wuhan, Hubei, Peoples R China [4]Huazhong Univ Sci & Technol, Oncol, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China [5]Guangzhou Mil Command PLA, Dept Thorac Surg, Gen Hosp, Guangzhou, Guangdong, Peoples R China [6]Guangxi Med Univ, Dept Thorac Surg, Affiliated Tumor Hosp, Nanning, Peoples R China [7]Guangxi Univ Chinese Med, Affiliated Hosp 1, Nanning, Peoples R China [8]Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Guangdong, Peoples R China [9]Sun Yat Sen Univ, Dept Thorac Surg, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China [10]OrigiMed, Shanghai, Peoples R China
出处：
ISSN：

关键词： HER2 afatinib lung cancer

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2016]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者：
第一作者单位： [1]Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Fang W.,Zhao S.,Liang Y.,et al.Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer[J].JOURNAL OF THORACIC ONCOLOGY.2018,13(12):S1080-S1080.
APA：
Fang, W.,Zhao, S.,Liang, Y.,Yang, Y.,Yang, L....&Zhang, L..(2018).Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer.JOURNAL OF THORACIC ONCOLOGY,13,(12)
MLA：
Fang, W.,et al."Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer".JOURNAL OF THORACIC ONCOLOGY 13..12(2018):S1080-S1080

相关文献

[1]Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma [2]Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma [3]Consensus for HER2 Alterations Testing in Non-small Cell Lung Cancer (vol 7, 100395, 2022) [4]Consensus for HER2 alterations testing in non-small-cell lung cancer [5]Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer [6]异鼠李素抑制耐吉非替尼人肺癌细胞PC9增殖的研究术 [7]Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China [8]First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial [9]Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705) [10]Primary Intrapulmonary Thymoma Mimicking Lung Cancer

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）